Connection

Rachel Tomko to Humans

Back to Details
This is a "connection" page, showing publications Rachel Tomko has written about Humans.
Rachel Tomko
Connection Strength
0.641
Humans
  1. Distress tolerance and reactivity to negative affective cues in naturalistic environments of cannabis-using emerging adults. Drug Alcohol Depend. 2022 09 01; 238:109588.
    View in: PubMed
    Score: 0.033
  2. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
    View in: PubMed
    Score: 0.031
  3. Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers. Nicotine Tob Res. 2020 01 27; 22(1):81-88.
    View in: PubMed
    Score: 0.028
  4. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
    View in: PubMed
    Score: 0.027
  5. An electronic, smart lighter to measure cigarette smoking: A pilot study to assess feasibility and initial validity. Addict Behav. 2019 11; 98:106052.
    View in: PubMed
    Score: 0.027
  6. Methods to reduce the incidence of false negative trial results in substance use treatment research. Curr Opin Psychol. 2019 12; 30:35-41.
    View in: PubMed
    Score: 0.026
  7. The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine. Addict Behav. 2018 10; 85:26-30.
    View in: PubMed
    Score: 0.025
  8. Introduction to the special issue: Utilizing ambulatory assessment to better understand the etiology, maintenance, treatment, and remission of addictive disorders. Addict Behav. 2018 08; 83:1-4.
    View in: PubMed
    Score: 0.024
  9. Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse. 2019; 45(1):26-41.
    View in: PubMed
    Score: 0.024
  10. Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
    View in: PubMed
    Score: 0.024
  11. Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology (Berl). 2017 Feb; 234(3):427-435.
    View in: PubMed
    Score: 0.022
  12. Personalizing substance use treatment based on pre-treatment impulsivity and sensation seeking: A review. Drug Alcohol Depend. 2016 Oct 01; 167:1-7.
    View in: PubMed
    Score: 0.022
  13. The structure of the UPPS-R-Child impulsivity scale and its relations with substance use outcomes among treatment-seeking adolescents. Drug Alcohol Depend. 2016 Apr 01; 161:276-83.
    View in: PubMed
    Score: 0.021
  14. Undifferentiated negative affect and impulsivity in borderline personality and depressive disorders: A momentary perspective. J Abnorm Psychol. 2015 Aug; 124(3):740-753.
    View in: PubMed
    Score: 0.020
  15. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014 Oct; 28(5):734-50.
    View in: PubMed
    Score: 0.019
  16. Measuring impulsivity in daily life: the momentary impulsivity scale. Psychol Assess. 2014 Jun; 26(2):339-49.
    View in: PubMed
    Score: 0.018
  17. Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial. BMC Psychol. 2023 Jan 25; 11(1):25.
    View in: PubMed
    Score: 0.008
  18. Characterization of Salivary Progesterone in Female Smokers. Nicotine Tob Res. 2022 10 26; 24(11):1829-1833.
    View in: PubMed
    Score: 0.008
  19. Gender parity and homophily in the Drug and Alcohol Dependence editorial process. Drug Alcohol Depend. 2022 07 01; 236:109493.
    View in: PubMed
    Score: 0.008
  20. Parent-Child Concordance and Discordance in Family Violence Reporting: A Descriptive Analysis from the Adolescent Brain Cognitive Development Study?. J Interpers Violence. 2023 01; 38(1-2):NP646-NP669.
    View in: PubMed
    Score: 0.008
  21. Reporting Treatment Fidelity in Behavioral Tobacco Treatment Clinical Trials: Scoping Review and Measurement Recommendations. Nicotine Tob Res. 2022 02 01; 24(2):150-159.
    View in: PubMed
    Score: 0.008
  22. A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth. Drug Alcohol Depend. 2022 03 01; 232:109311.
    View in: PubMed
    Score: 0.008
  23. The estimand framework and its application in substance use disorder clinical trials: a case study. Am J Drug Alcohol Abuse. 2021 11 02; 47(6):658-663.
    View in: PubMed
    Score: 0.008
  24. Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug Alcohol Depend. 2021 08 01; 225:108815.
    View in: PubMed
    Score: 0.008
  25. Mobile, Remote, and Individual Focused: Comparing Breath Carbon Monoxide Readings and Abstinence Between Smartphone-Enabled and Stand-Alone Monitors. Nicotine Tob Res. 2021 03 19; 23(4):741-747.
    View in: PubMed
    Score: 0.007
  26. Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study. Front Endocrinol (Lausanne). 2020; 11:549928.
    View in: PubMed
    Score: 0.007
  27. Racial Disparities in Elementary School Disciplinary Actions: Findings From the ABCD Study. J Am Acad Child Adolesc Psychiatry. 2021 08; 60(8):998-1009.
    View in: PubMed
    Score: 0.007
  28. Remote Methods for Conducting Tobacco-Focused Clinical Trials. Nicotine Tob Res. 2020 12 12; 22(12):2134-2140.
    View in: PubMed
    Score: 0.007
  29. Impact of disaster exposure severity: Cascading effects across parental distress, adolescent PTSD symptoms, as well as parent-child conflict and communication. Soc Sci Med. 2020 11; 264:113293.
    View in: PubMed
    Score: 0.007
  30. Piloting of the Just Say Know prevention program: a psychoeducational approach to translating the neuroscience of addiction to youth. Am J Drug Alcohol Abuse. 2021 01 02; 47(1):16-25.
    View in: PubMed
    Score: 0.007
  31. Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. Nicotine Tob Res. 2020 07 16; 22(8):1374-1382.
    View in: PubMed
    Score: 0.007
  32. Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers. Psychoneuroendocrinology. 2020 10; 120:104752.
    View in: PubMed
    Score: 0.007
  33. Increases in endogenous progesterone attenuate smoking in a cohort of nontreatment seeking women: An exploratory prospective study. Addict Biol. 2021 03; 26(2):e12918.
    View in: PubMed
    Score: 0.007
  34. The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. Psychopharmacology (Berl). 2020 Feb; 237(2):543-555.
    View in: PubMed
    Score: 0.007
  35. Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. JAMA Pediatr. 2019 12 01; 173(12):1146-1153.
    View in: PubMed
    Score: 0.007
  36. Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies. Curr Psychiatry Rep. 2019 09 14; 21(10):96.
    View in: PubMed
    Score: 0.007
  37. Pharmacological Treatment of Youth Substance Use Disorders. J Child Adolesc Psychopharmacol. 2019 08; 29(7):559-572.
    View in: PubMed
    Score: 0.007
  38. Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults. Drug Alcohol Depend. 2019 05 01; 198:105-111.
    View in: PubMed
    Score: 0.006
  39. Tobacco and cannabis co-use: Drug substitution, quit interest, and cessation preferences. Exp Clin Psychopharmacol. 2019 Jun; 27(3):265-275.
    View in: PubMed
    Score: 0.006
  40. Tobacco and cannabis co-use and interrelatedness among adults. Addict Behav. 2019 03; 90:354-361.
    View in: PubMed
    Score: 0.006
  41. Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend. 2018 11 01; 192:59-66.
    View in: PubMed
    Score: 0.006
  42. Impact of cannabis legalization on treatment and research priorities for cannabis use disorder. Int Rev Psychiatry. 2018 06; 30(3):216-225.
    View in: PubMed
    Score: 0.006
  43. Acceptability and compliance with a remote monitoring system to track smoking and abstinence among young smokers. Am J Drug Alcohol Abuse. 2018; 44(5):561-570.
    View in: PubMed
    Score: 0.006
  44. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
    View in: PubMed
    Score: 0.006
  45. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017 10; 81:53-58.
    View in: PubMed
    Score: 0.006
  46. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
    View in: PubMed
    Score: 0.006
  47. Countering Craving with Disgust Images: Examining Nicotine Withdrawn Smokers' Motivated Message Processing of Anti-Tobacco Public Service Announcements. J Health Commun. 2017 03; 22(3):254-261.
    View in: PubMed
    Score: 0.006
  48. Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
    View in: PubMed
    Score: 0.005
  49. Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder. J Subst Abuse Treat. 2016 Apr; 63:72-7.
    View in: PubMed
    Score: 0.005
  50. Does hangover influence the time to next drink? An investigation using ecological momentary assessment. Alcohol Clin Exp Res. 2014 May; 38(5):1461-9.
    View in: PubMed
    Score: 0.005
  51. Gene-environment studies and borderline personality disorder: a review. Curr Psychiatry Rep. 2013 Jan; 15(1):336.
    View in: PubMed
    Score: 0.004
  52. The influence of general identity disturbance on reports of lifetime substance use disorders and related outcomes among sexual minority adults with a history of substance use. Psychol Addict Behav. 2011 Sep; 25(3):530-41.
    View in: PubMed
    Score: 0.004
  53. Distinguishing general and specific personality disorder features and implications for substance dependence comorbidity. J Abnorm Psychol. 2011 Aug; 120(3):656-69.
    View in: PubMed
    Score: 0.004
  54. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010 Aug; 24(4):412-26.
    View in: PubMed
    Score: 0.004
  55. Longitudinal associations in borderline personality disorder features: Diagnostic Interview for Borderlines-Revised (DIB-R) scores over time. J Pers Disord. 2010 Jun; 24(3):377-91.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.